🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. tiotropium high dose

    Boehringer Ingelheim

    Asthma

    phase 3 small molecule completed

    1 trial

  2. tobacco abstinent contingent

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 3 other completed

    1 trial

  3. topiramate

    Ultragenyx UK Limited

    Lennox-Gastaut Syndrome

    phase 3 small molecule completed

    1 trial

  4. toripalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Cancer

    phase 3 small molecule active

    1 trial

  5. turoctocog alfa pegol

    Novo Nordisk A/S

    Congenital Bleeding Disorder

    phase 3 small molecule completed

    2 trials

  6. valoctocogene roxaparvovec

    BioMarin Pharmaceutical Australia Pty Ltd

    Hemophilia A

    phase 3 mab active

    5 trials

  7. vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU)

    United Therapeutics Europe Ltd

    Mortality Through Six Months of Age

    phase 3 other completed

    1 trial

  8. warfarin

    Boehringer Ingelheim

    Atrial Fibrillation

    phase 3 small molecule completed

    1 trial

  9. whole-cell pertussis vaccine

    Ultragenyx UK Limited

    Pertussis

    phase 3 mab completed

    1 trial

  10. zoledronic acid

    Novartis Pharmaceuticals

    Paget's Disease of Bone

    phase 3 small molecule completed

    1 trial

  11. zongertinib

    Boehringer Ingelheim

    Lung Cancer, Non-squamous, Non-small Cell

    phase 3 small molecule active

    1 trial

  12. "Endostar"

    The First People's Hospital of Lianyungang

    Esophageal

    phase 2 small molecule terminated

    1 trial

  13. -

    The George Institute

    Cytomegalovirus infection post allogeneic allogeneic HLA-identical familial PHT

    phase 2 small molecule active

    1 trial

  14. -, -, PACLITAXEL , MK-2870, -, MK-1022, RAMUCIRUMAB , MK-2870, PARACETAMOL

    Merck Sharp and Dohme

    Gastroesophageal cancer

    phase 2 small molecule active

    1 trial

  15. -, CYCLOPHOSPHAMIDE, Cesnicabtagene autoleucel, PARACETAMOL, FLUDARABINE, LENALIDOMIDE, RoActemra 20 mg/mL concentrate for solution for infusion

    The George Institute

    Plasma cell leukaemia

    phase 2 small molecule active

    1 trial

  16. -, Raludotatug Deruxtecan, MK-4830, MK-1308A, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib, Lenvatinib, MK-4280A, DEXAMETHASONE , APREPITANT

    Merck Sharp and Dohme

    Participants with extensive-stage small cell lung cancer

    phase 2 small molecule active

    1 trial

  17. -aminosalicylic acid

    Ultragenyx UK Limited

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  18. 0.9% Sodium chloride - inhalation solution

    Arrowhead Pharmaceuticals Ireland Limited

    Inflammatory Lung Disease

    phase 2 small molecule active

    1 trial

  19. 1% tenofovir gel

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 2 small molecule completed

    1 trial

  20. 10 GE Xenokidney

    United Therapeutics Europe Ltd

    ESRD (End-Stage Renal Disease)

    phase 2 mab active

    1 trial

  21. 12.5mg sunitinib with Cisplatin and Gemcitabine

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma

    phase 2 small molecule completed

    1 trial

  22. 177Lu-PSMA I&T_IRSTIRCCS

    Istituto Gentili S.r.l.

    Oligometastatic prostate carcinoma

    phase 2 small molecule active

    1 trial

  23. 177Lu-PSMA I&T_IRSTIRCCS

    Istituto Gentili S.r.l.

    PSMA PET/CT positive advanced/metastatic tumours

    phase 2 small molecule active

    1 trial

  24. 2 cycles of combined drug induction therapy: every 3 weeks for 2 cycles; After ,synchronous radiotherapy and chemotherapy combined immunotherapy

    The First People's Hospital of Lianyungang

    Cervical Cancer Stage IVA

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources